Literature DB >> 7614313

The treatment of vascular access graft dysfunction: a nephrologist's view and experience.

G A Beathard1.   

Abstract

Chronic hemodialysis, as it is practiced today, is heavily dependent on the use of the expanded polytetrafluoroethylene graft for vascular access, although it is prone to the problem of venous stenosis and its sequela, thrombosis. The natural history of untreated venous stenosis is to decrease the efficiency of dialysis and to limit the life expectancy of the graft. Prospective treatment of venous stenosis has been advocated and percutaneous transluminal angioplasty (PTA) has been shown to be safe and reasonably effective for this purpose. Because there is no optimum screening test for venous stenosis, patient selection for PTA is particularly important. The use of a group of clinical indicators that serve to indicate a significant degree of graft dysfunction has been recommended for this purpose. Long-term patency may be better when venous stenosis is surgically revised; however, PTA has a number of advantages, especially the preservation of potential vascular access sites. Endovascular metallic stents have been used to preserve patency following PTA with disappointing results except in selected cases with central lesions. Three types of percutaneous thrombolysis have been studied for the treatment of thrombosed access grafts. The technique of pharmacological thrombolysis in which a lytic enzyme is infused into the clotted graft has proven to be unsatisfactory. The more recently developed technique of pharmacomechanical thrombolysis (PMT) has proven to be practical for use in the dialysis patient. This procedure consists of two components, a pharmacological phase in which lytic enzyme is administered and a mechanical phase in which the residual clot is macerated and removed to restore flow. This technique offers the benefits of being quick, effective, and safe. Additionally, it combines angiographic evaluation of the access, thrombolysis, and angioplasty of stenotic lesions. Mechanical thrombolysis, performed in a manner identical to PMT except that saline is used in place of the lytic enzyme, has been shown to be equally effective and safe.

Entities:  

Mesh:

Year:  1994        PMID: 7614313     DOI: 10.1016/s1073-4449(12)80044-6

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  8 in total

1.  Long-term outcome of a cuffed expanded PTFE graft for hemodialysis vascular access.

Authors:  George Tsoulfas; Martin Hertl; Dicken S C Ko; Nahel Elias; Francis L Delmonico; Linda Romano; Isabel Fernandes; David Schoenfeld; Tatsuo Kawai
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

2.  Polymer-Based Nitric Oxide Therapies: Recent Insights for Biomedical Applications.

Authors:  Michele C Jen; María C Serrano; Robert van Lith; Guillermo A Ameer
Journal:  Adv Funct Mater       Date:  2012-01-25       Impact factor: 18.808

Review 3.  Definitions and End Points for Interventional Studies for Arteriovenous Dialysis Access.

Authors:  Gerald A Beathard; Charmaine E Lok; Marc H Glickman; Ahmed A Al-Jaishi; Donna Bednarski; David L Cull; Jeffery H Lawson; Timmy C Lee; Vandana D Niyyar; Donna Syracuse; Scott O Trerotola; Prabir Roy-Chaudhury; Surendra Shenoy; Margo Underwood; Haimanot Wasse; Karen Woo; Theodore H Yuo; Thomas S Huber
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-20       Impact factor: 8.237

Review 4.  Challenges and novel therapies for vascular access in haemodialysis.

Authors:  Jeffrey H Lawson; Laura E Niklason; Prabir Roy-Chaudhury
Journal:  Nat Rev Nephrol       Date:  2020-08-24       Impact factor: 28.314

5.  Adventitial endothelial implants reduce matrix metalloproteinase-2 expression and increase luminal diameter in porcine arteriovenous grafts.

Authors:  Helen M Nugent; Robert Tjin Tham Sjin; Desmond White; Luther G Milton; Roberto J Manson; Jeffrey H Lawson; Elazer R Edelman
Journal:  J Vasc Surg       Date:  2007-09       Impact factor: 4.268

6.  Hemodynamic Shear Stress and Endothelial Dysfunction in Hemodialysis Access.

Authors:  Michelle K Fitts; Daniel B Pike; Kasey Anderson; Yan-Ting Shiu
Journal:  Open Urol Nephrol J       Date:  2014

7.  Surveillance and monitoring of dialysis access.

Authors:  Lalathaksha Kumbar; Jariatul Karim; Anatole Besarab
Journal:  Int J Nephrol       Date:  2011-11-22

8.  Five Year Outcomes in Patients with End Stage Renal Disease Who Received a Bioengineered Human Acellular Vessel for Dialysis Access.

Authors:  Tomasz Jakimowicz; Stanislaw Przywara; Jakub Turek; Alison Pilgrim; Michal Macech; Norbert Zapotoczny; Tomasz Zubilewicz; Jeffrey H Lawson; Laura E Niklason
Journal:  EJVES Vasc Forum       Date:  2022-01-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.